Emicizumab (Anti-F9 & Factor IX) is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab (Anti-F9 & Factor IX) can be used for hemophilia A research [1].
In Vivo, Emicizumab (Anti-F9 & Factor IX) (1.5-10 mg/kg, IV, 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia A bleeding model, with an FVIII equivalence of 9 U/dL[1]. Emicizumab (Anti-F9 & Factor IX) (3 mg/kg, iv) provides additive hemostatic activity when given in combination with low-dose FVIII (10 U/dL)[1].
References:
[1]. Ferrière S, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020 Aug 6;136(6):740-748.
In Vivo, Emicizumab (Anti-F9 & Factor IX) (1.5-10 mg/kg, IV, 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia A bleeding model, with an FVIII equivalence of 9 U/dL[1]. Emicizumab (Anti-F9 & Factor IX) (3 mg/kg, iv) provides additive hemostatic activity when given in combination with low-dose FVIII (10 U/dL)[1].
References:
[1]. Ferrière S, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020 Aug 6;136(6):740-748.